Trump Unveils Historic Drug Pricing Pact with Pharmaceutical Giants
President Donald Trump has secured a landmark drug pricing agreement with Regeneron and other major pharmaceutical companies, reducing medication costs for Medicaid and cash payers. In exchange for tariff exemptions, the deal includes 'most-favored nation' pricing and significant U.S. investments. Regeneron will also offer Praluent at a reduced price.
President Donald Trump announced a significant drug pricing deal with Regeneron Pharmaceuticals and 16 other major firms on Thursday, aiming to lower U.S. medication costs.
The agreement includes 'most-favored nation' pricing, securing steep discounts for government programs and cash payers, with drugmakers getting three-year exemptions from tariffs in return.
Regeneron shares rose 2.6%. The company has agreed to slash Medicaid prices and offer its gene therapy Otarmeni for free to children with hearing loss. It will also reduce the price of Praluent and list it on Trump's new platform, TrumpRx.gov.
ALSO READ
-
Trump's 'Gold Card': Gateway or Gimmick?
-
Trump says Israel and Lebanon agree to extend ceasefire by 3 weeks after he meets with countries' envoys at White House, reports AP.
-
Trump Invites Putin to Miami G-20 Summit
-
Trump Strikes Deal with Regeneron for Discounted Drug Prices
-
Luring Investors: The Trump Gold Card Visa One Year In
Google News